» Articles » PMID: 29937940

Predicting Hepatocellular Carcinoma Development for Cirrhosis Patients Via Methylation Detection of Heparocarcinogenesis-related Genes

Overview
Journal J Cancer
Specialty Oncology
Date 2018 Jun 26
PMID 29937940
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Most hepatocellular carcinoma (HCC) patients have undergone a progression from chronic hepatitis, then liver cirrhosis (LC), and finally to carcinoma. The objective of this study was to elucidate risk factors to predict HCC development for cirrhosis patients. Multiple methylated specific PCR (MSP) was applied to determine methylation status of heparocarcinogenesis-related genes in 396 tissue and plasma specimens and multivariate cox model was used to analyze the relationship between risk variables and HCC development among cirrhosis patients, followed up in a median period of 30 months. Among 105 LC cases, HCC incidence rate at 30 months was 30.48% (32/105), which were statistically associated with patients' age and aberrant methylation of , , and (<0.05). Receiver operating characteristic (ROC) curve showed the overall predictive accuracy reached the highest (90.7%) if the four risk variables were concurrent to predict HCC development. Moreover, along with the growth of age from 0-40, 40-55, to 55-70 years or the increased number of aberrantly-methylated gene from 0-1 to 2-3, the HCC incidence rate of cirrhosis patients rised from 10.00%, 12.28% to 82.14% and 17.44% to 89.47%, separately. Thus, based on combined analysis with diverse age and number of aberrantly-methylated gene, 105 cases were divided into five groups and computed their respective HCC incidecne rate to categorize them into different risk groups. Of note, A significant lifting of HCC incidence rate in the high-risk group (40-55 years coupled with 2-3 aberrantly-methylated genes, 55-70 years coupled with 0-1 aberrantly-methylated gene, 55-70 years coupled with 2-3 aberrantly-methylated genes; n=33) was observed compared with the low-risk group (0-40 years coupled with 0-1 aberrantly-methylated gene, 40-55 years coupled with 0-1 aberrantly-methylated gene; (n=72) (<0.01). Ultimately, high-risk cirrhosis patients with 55-over years or 2-3 aberrantly-methylated genes should be paid more attention to be regularly screened with HCC development.

Citing Articles

Liquid Liver Biopsy for Disease Diagnosis and Prognosis.

Tsoneva D, Ivanov M, Vinciguerra M J Clin Transl Hepatol. 2024; 11(7):1520-1541.

PMID: 38161500 PMC: 10752811. DOI: 10.14218/JCTH.2023.00040.


Hepatocellular carcinoma detection via targeted enzymatic methyl sequencing of plasma cell-free DNA.

Guo P, Zheng H, Li Y, Li Y, Xiao Y, Zheng J Clin Epigenetics. 2023; 15(1):2.

PMID: 36600275 DOI: 10.1186/s13148-022-01420-6.


Long interspersed nuclear element 1 hypomethylation has novel prognostic value and potential utility in liquid biopsy for oral cavity cancer.

Misawa K, Yamada S, Mima M, Nakagawa T, Kurokawa T, Imai A Biomark Res. 2020; 8:53.

PMID: 33110605 PMC: 7585304. DOI: 10.1186/s40364-020-00235-y.


Association between gene methylation and HBV infection in hepatocellular carcinoma: A meta-analysis.

Zhang C, Huang C, Sui X, Zhong X, Yang W, Hu X J Cancer. 2019; 10(25):6457-6465.

PMID: 31772678 PMC: 6856736. DOI: 10.7150/jca.33005.


Influence of some methylated hepatocarcinogenesis-related genes on the response to antiviral therapy and development of fibrosis in chronic hepatitis C patients.

Mostafa W, Al-Dahr M, Omran D, Abdullah Z, Elmasry S, Ibrahim M Clin Mol Hepatol. 2019; 26(1):60-69.

PMID: 31630500 PMC: 6940485. DOI: 10.3350/cmh.2019.0051.


References
1.
Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M . Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010; 52(2):518-27. DOI: 10.1002/hep.23691. View

2.
Wang J, Qin Y, Li B, Sun Z, Yang B . Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem. 2006; 39(4):344-8. DOI: 10.1016/j.clinbiochem.2006.01.008. View

3.
Dong Y, Wang A . Aberrant DNA methylation in hepatocellular carcinoma tumor suppression (Review). Oncol Lett. 2014; 8(3):963-968. PMC: 4114628. DOI: 10.3892/ol.2014.2301. View

4.
Villanueva A, Llovet J . Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning. Nat Rev Clin Oncol. 2014; 11(2):73-4. DOI: 10.1038/nrclinonc.2013.243. View

5.
Huang W, Li T, Yang W, Chai X, Chen K, Wei L . Analysis of DNA methylation in plasma for monitoring hepatocarcinogenesis. Genet Test Mol Biomarkers. 2015; 19(6):295-302. PMC: 4487245. DOI: 10.1089/gtmb.2014.0292. View